Citrus off-season.

Did you know roughly one-quarter of cholangiocarcinomas have mutations in isocitrate dehydrogenase-1 (mIDH1)? Ivosidenib is a novel(ish) drug targeting precisely mIDH1, already approved for AML. This phase 1 dose-finding study found no max-tolerated dose, meaning this drug is getting ready for prime time with a phase 3 trial for efficacy. | Lowery, Lancet Gastroenterol Hepatol 2019